Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

Ochsner Health, Ochsner Cancer Institute developed a program to remotely monitor patients on intravenous or oral anti-cancer treatment.
SKIN CANCER Awareness Month SKIN CANCER IS THE MOST COMMON CANCER WORLDWIDE AND IN THE US1 More than 9500 people are diagnosed with skin cancer every day in the US2 Epidemiology of skin cancer About 5.4 million nonmelanoma skin cancer (NMSC) cases are diagnosed each year in the US. About two-thirds of these cases are basal cell carcinoma (BCC) and one-third are squamous cell carcinoma …
EXECUTIVE OFFICE: 1801 Research Boulevard • Suite 400 • Rockville, MD 20850-3184 • Phone: 301.984.9496 • Fax: 301.770.1949 www.accc-cancer.org OFFICERS President Nadine J. Barrett, PhD, MA, MS, FACCC Wake Forest University School of Medicine and Atrium Health Durham, North Carolina President-Elect Una Hopkins, RN, FNP-BC, DNP, FACCC Montefiore Medical Center Bronx, New …
LIO 2022 Cover Eden Roc Miami Beach January 28-29, 2022 Welcome Welcome to the 2022 ACCC and Oncology State Societies Leaders in Oncology program. ACCC has been privileged to engage with—and support—quality care delivery on both the national and state level for more than 40 years. Since its provider-led beginnings, ACCC has worked with oncology leaders from around …
2013Tarceva_NSCLC_update
Oral Oncolytic Adherence and Toxicity Monitoring Cara Harshberger, PharmD, BCOP Paula Eskam, MS, RDN, PMP Erin Davis, RN, BS Ivinson Memorial Hospital Meredith & Jeannie Ray Cancer Center Laramie, WY March 2023 Cara Ivinson Memorial Hospital has provided world-class care to our community since 1917. We are a 99-bed facility, proudly located in …
PowerPoint Presentation COVID-19 in Oncology Patients North Carolina Oncology Society/South Carolina Oncology Society: Joint Conference February 11-12, 2022 Charles de Comarmond MD Associate Professor of Medicine and Infectious Diseases Disclosures and disclaimers Charles D. Comarmond, MD, has no real or apparent financial relationships to disclose. The views …
Impact-of-Cancer-Scale-Tool
DOSING AND TESTING REQUIREMENTS Before prescribing KEYTRUDA, please read the accompanying Prescribing Information. The Medication Guide also is available. SELECTED SAFETY INFORMATION Immune-Mediated Pneumonitis • KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including …
Microsoft PowerPoint - DiGiaimo Slides 9/21/2018 1 Copyright® 2018 RCI All Rights Reserved. Do Not Duplicate. Work product, information and guidance provided by RCI are subject to the terms and limitations provided at http://www.revenuecycleinc.com/disclaimer Prepare for Reimbursement Challenges of the Next 12 Months Presented by Ron DiGiaimo, MBA, FACHE info@revenuecycleinc.com …
MF 2022 Updates in Myeloproliferative Neoplasms Hana Safah MD Professor of Medicine Director of Tulane Cellular Therapy / Heme malignancy Disclosure of Conflicts of Interests Hana Safah, MD has the following financial relationships to disclose: Speaker – Astellas, BMS, GSK, Incyte,Jazz, Sanofi Novel therapies vs HCT in MF • Expert opinion is to recommend …
PowerPoint Presentation State Legislative Efforts to Increase Patient Care Gray Jodon, MD RMOS Policy Committee Chair Hematologist/Oncologist, Denver Health Conflict of Interests •None to report Learning Objectives •Review the Colorado Prescription Drug Affordability Review Board and Advisory Council (PDAB/PDACC) upper payment limit selection process …
MJ03-How-Medicare-Reimbursement-Affects-Our-Patients
November 28, 2022 The Honorable Charles Schumer Majority Leader United States Senate Washington, DC 20510 The Honorable Mitch McConnell Republican Leader United States Senate Washington, DC 20510 The Honorable Nancy Pelosi Speaker United States House of Representatives Washington, DC 20515 The Honorable Kevin McCarthy Republican …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Imfinzi® (durvalumab) – AstraZeneca’s PD-L1 inhibitor was newly approved for use, in combination with gemcitabine and cisplatin, as treatment for adult patients with locally advanced or metastatic biliary tract cancer (BTC). The expansion beyond lung cancer—where the IO agent …
There are a host of biomarkers associated with specific cancer types, disease diagnosis or prognosis, and treatment decisions and monitoring.
Presented at the 2020 ASCO Virtual Scientific Program
This is a visual representation of an online publication from the American Society of Clinical Oncology 2022 Annual Meeting, June 3 - 7, 2022.
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) Renato G. Martins, MD, MPH Medical Director, Thoracic/Head and Neck; General Oncology and Hematology Seattle Cancer Care Alliance July 28, 2015 11:30 am – 12:30 pm, EST ICLIO e-Course 02 1 Objectives By the end of this e-course, participants will be able to: Understand the current …
Mint Simple Lined Minimalist Medical Presentation Presented by Laura Kerns , MPH, RD, CSO, LDN, FAND Oral Vitamins and Nutraceuticals in Oncology: Facts over Fallacy Relevant Financial Disclosures Avanos Medical -Speaker Background Uses during and after treatment: what we know The hot list Making safe choices Final thoughts References …